Cargando…
Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand
There is a key problem in randomised clinical trials as outcomes can be distorted due to informative post‐randomisation events. This is inadequately addressed by the use of traditional intention‐to‐treat or per protocol analysis sets and often either ignored or wrongly labelled as missing data. As a...
Autores principales: | Pétavy, Frank, Guizzaro, Lorenzo, Antunes dos Reis, Inês, Teerenstra, Steven, Roes, Kit C.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319001/ https://www.ncbi.nlm.nih.gov/pubmed/31883123 http://dx.doi.org/10.1111/bcp.14195 |
Ejemplares similares
-
Estimation of treatment effects in short‐term depression studies. An evaluation based on the ICH E9(R1) estimands framework
por: Mitroiu, Marian, et al.
Publicado: (2022) -
A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
por: Mitroiu, M., et al.
Publicado: (2020) -
Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices
por: Abed, Inga, et al.
Publicado: (2022) -
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2017) -
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017)